Do analysts recommend INAB or PBM?

IN8bio presently has a consensus target price of $4.00, indicating a potential upside of 159.74%. Given IN8bio's stronger consensus rating and higher possible upside, equities research analysts clearly believe IN8bio is more favorable than Psyence Biomedical. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score IN8bio 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Psyence Biomedical 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher valuation and earnings, INAB or PBM?

IN8bio is trading at a lower price-to-earnings ratio than Psyence Biomedical, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio IN8bio N/A N/A -$19.44M -$2.61 N/A Psyence Biomedical N/A N/A $1.01M $25.34 0.15

Is INAB or PBM more profitable?

Psyence Biomedical's return on equity of 0.00% beat IN8bio's return on equity. Company Net Margins Return on Equity Return on Assets IN8bio N/A -96.39% -80.18% Psyence Biomedical N/A N/A N/A

Do analysts prefer PBM or KTTA?

Pasithea Therapeutics has a consensus price target of $3.00, suggesting a potential upside of 383.87%. Given Pasithea Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Pasithea Therapeutics is more favorable than Psyence Biomedical. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Psyence Biomedical 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Pasithea Therapeutics 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has better valuation & earnings, PBM or KTTA?

Pasithea Therapeutics is trading at a lower price-to-earnings ratio than Psyence Biomedical, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Psyence Biomedical N/A N/A $1.01M $25.34 0.15 Pasithea Therapeutics N/A N/A -$20.43M -$2.08 N/A

Is PBM or KTTA more profitable?

Psyence Biomedical's return on equity of 0.00% beat Pasithea Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Psyence Biomedical N/A N/A N/A Pasithea Therapeutics N/A -57.44% -53.61%

Do analysts prefer PBM or ANEB?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Psyence Biomedical 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Anebulo Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Which has better earnings & valuation, PBM or ANEB?

Anebulo Pharmaceuticals is trading at a lower price-to-earnings ratio than Psyence Biomedical, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Psyence Biomedical N/A N/A $1.01M $25.34 0.15 Anebulo Pharmaceuticals N/A N/A -$8.48M -$0.19 N/A

Is PBM or ANEB more profitable?

Psyence Biomedical's return on equity of 0.00% beat Anebulo Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Psyence Biomedical N/A N/A N/A Anebulo Pharmaceuticals N/A -74.57% -68.96%

Do analysts prefer PBM or GRDX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Psyence Biomedical 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Entero Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is PBM or GRDX more profitable?

Psyence Biomedical's return on equity of 0.00% beat Entero Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Psyence Biomedical N/A N/A N/A Entero Therapeutics N/A -49.81% -11.02%

Do analysts recommend PBM or NAII?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Psyence Biomedical 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Natural Alternatives International 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Psyence Biomedical (PBM) Competitors

$3.69 -0.26 (-6.58%)

Closing price 04:00 PM Eastern

Extended Trading

$3.73 +0.04 (+1.08%)

As of 07:54 PM Eastern

Compare

PBM vs. INAB, KTTA, ANEB, GRDX, and NAII

Should you buy Psyence Biomedical stock or one of its competitors? MarketBeat compares Psyence Biomedical with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Psyence Biomedical include IN8bio (INAB), Pasithea Therapeutics (KTTA), Anebulo Pharmaceuticals (ANEB), Entero Therapeutics (GRDX), and Natural Alternatives International (NAII). These companies are all part of the "pharmaceutical products" industry.

How does Psyence Biomedical compare to IN8bio?

IN8bio (NASDAQ:INAB) and Psyence Biomedical (NASDAQ:PBM) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, earnings, dividends, analyst recommendations, valuation and media sentiment.

92.1% of IN8bio shares are held by institutional investors. Comparatively, 77.4% of Psyence Biomedical shares are held by institutional investors. 14.5% of IN8bio shares are held by company insiders. Comparatively, 3.6% of Psyence Biomedical shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, IN8bio had 4 more articles in the media than Psyence Biomedical. MarketBeat recorded 4 mentions for IN8bio and 0 mentions for Psyence Biomedical. Psyence Biomedical's average media sentiment score of 1.87 beat IN8bio's score of 0.54 indicating that Psyence Biomedical is being referred to more favorably in the news media.

Company	Overall Sentiment
IN8bio	Positive
Psyence Biomedical	Very Positive

IN8bio has a beta of 0.19, meaning that its stock price is 81% less volatile than the broader market. Comparatively, Psyence Biomedical has a beta of 1.64, meaning that its stock price is 64% more volatile than the broader market.

IN8bio is trading at a lower price-to-earnings ratio than Psyence Biomedical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IN8bio	N/A	N/A	-$19.44M	-$2.61	N/A
Psyence Biomedical	N/A	N/A	$1.01M	$25.34	0.15

IN8bio presently has a consensus target price of $4.00, indicating a potential upside of 159.74%. Given IN8bio's stronger consensus rating and higher possible upside, equities research analysts clearly believe IN8bio is more favorable than Psyence Biomedical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IN8bio	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Psyence Biomedical	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Psyence Biomedical's return on equity of 0.00% beat IN8bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IN8bio	N/A	-96.39%	-80.18%
Psyence Biomedical	N/A	N/A	N/A

Summary

Psyence Biomedical beats IN8bio on 7 of the 13 factors compared between the two stocks.

How does Psyence Biomedical compare to Pasithea Therapeutics?

Psyence Biomedical (NASDAQ:PBM) and Pasithea Therapeutics (NASDAQ:KTTA) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, media sentiment, institutional ownership, risk, valuation, dividends, earnings and analyst recommendations.

Psyence Biomedical's return on equity of 0.00% beat Pasithea Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Psyence Biomedical	N/A	N/A	N/A
Pasithea Therapeutics	N/A	-57.44%	-53.61%

Pasithea Therapeutics is trading at a lower price-to-earnings ratio than Psyence Biomedical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Psyence Biomedical	N/A	N/A	$1.01M	$25.34	0.15
Pasithea Therapeutics	N/A	N/A	-$20.43M	-$2.08	N/A

In the previous week, Pasithea Therapeutics had 2 more articles in the media than Psyence Biomedical. MarketBeat recorded 2 mentions for Pasithea Therapeutics and 0 mentions for Psyence Biomedical. Psyence Biomedical's average media sentiment score of 1.87 beat Pasithea Therapeutics' score of 1.29 indicating that Psyence Biomedical is being referred to more favorably in the media.

Company	Overall Sentiment
Psyence Biomedical	Very Positive
Pasithea Therapeutics	Positive

77.4% of Psyence Biomedical shares are held by institutional investors. Comparatively, 23.9% of Pasithea Therapeutics shares are held by institutional investors. 3.6% of Psyence Biomedical shares are held by company insiders. Comparatively, 2.0% of Pasithea Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Psyence Biomedical has a beta of 1.64, suggesting that its stock price is 64% more volatile than the broader market. Comparatively, Pasithea Therapeutics has a beta of 0.25, suggesting that its stock price is 75% less volatile than the broader market.

Pasithea Therapeutics has a consensus price target of $3.00, suggesting a potential upside of 383.87%. Given Pasithea Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Pasithea Therapeutics is more favorable than Psyence Biomedical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Psyence Biomedical	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Pasithea Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Psyence Biomedical beats Pasithea Therapeutics on 9 of the 13 factors compared between the two stocks.

How does Psyence Biomedical compare to Anebulo Pharmaceuticals?

Psyence Biomedical (NASDAQ:PBM) and Anebulo Pharmaceuticals (NASDAQ:ANEB) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, valuation, risk, earnings, media sentiment, institutional ownership and dividends.

77.4% of Psyence Biomedical shares are held by institutional investors. Comparatively, 28.4% of Anebulo Pharmaceuticals shares are held by institutional investors. 3.6% of Psyence Biomedical shares are held by company insiders. Comparatively, 80.6% of Anebulo Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Anebulo Pharmaceuticals is trading at a lower price-to-earnings ratio than Psyence Biomedical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Psyence Biomedical	N/A	N/A	$1.01M	$25.34	0.15
Anebulo Pharmaceuticals	N/A	N/A	-$8.48M	-$0.19	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Psyence Biomedical	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Anebulo Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Psyence Biomedical's return on equity of 0.00% beat Anebulo Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Psyence Biomedical	N/A	N/A	N/A
Anebulo Pharmaceuticals	N/A	-74.57%	-68.96%

In the previous week, Psyence Biomedical's average media sentiment score of 1.87 beat Anebulo Pharmaceuticals' score of 0.00 indicating that Psyence Biomedical is being referred to more favorably in the media.

Company	Overall Sentiment
Psyence Biomedical	Very Positive
Anebulo Pharmaceuticals	Neutral

Psyence Biomedical has a beta of 1.64, indicating that its stock price is 64% more volatile than the broader market. Comparatively, Anebulo Pharmaceuticals has a beta of -1.88, indicating that its stock price is 288% less volatile than the broader market.

Summary

Psyence Biomedical beats Anebulo Pharmaceuticals on 8 of the 10 factors compared between the two stocks.

How does Psyence Biomedical compare to Entero Therapeutics?

Psyence Biomedical (NASDAQ:PBM) and Entero Therapeutics (NASDAQ:GRDX) are both small-cap pharmaceutical products companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, profitability, media sentiment, dividends, risk, valuation, earnings and institutional ownership.

In the previous week, Psyence Biomedical's average media sentiment score of 1.87 beat Entero Therapeutics' score of 1.62 indicating that Psyence Biomedical is being referred to more favorably in the media.

Company	Overall Sentiment
Psyence Biomedical	Very Positive
Entero Therapeutics	Very Positive

77.4% of Psyence Biomedical shares are held by institutional investors. Comparatively, 12.3% of Entero Therapeutics shares are held by institutional investors. 3.6% of Psyence Biomedical shares are held by insiders. Comparatively, 0.8% of Entero Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Psyence Biomedical has higher earnings, but lower revenue than Entero Therapeutics. Entero Therapeutics is trading at a lower price-to-earnings ratio than Psyence Biomedical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Psyence Biomedical	N/A	N/A	$1.01M	$25.34	0.15
Entero Therapeutics	$40K	509.04	-$6.39M	-$1.88	N/A

Psyence Biomedical has a beta of 1.64, indicating that its stock price is 64% more volatile than the broader market. Comparatively, Entero Therapeutics has a beta of 1.8, indicating that its stock price is 80% more volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Psyence Biomedical	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Entero Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Psyence Biomedical's return on equity of 0.00% beat Entero Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Psyence Biomedical	N/A	N/A	N/A
Entero Therapeutics	N/A	-49.81%	-11.02%

Summary

Psyence Biomedical beats Entero Therapeutics on 9 of the 11 factors compared between the two stocks.

How does Psyence Biomedical compare to Natural Alternatives International?

Psyence Biomedical (NASDAQ:PBM) and Natural Alternatives International (NASDAQ:NAII) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, earnings, media sentiment, profitability, dividends, valuation, analyst recommendations and institutional ownership.

Psyence Biomedical has a net margin of 0.00% compared to Natural Alternatives International's net margin of -10.13%. Psyence Biomedical's return on equity of 0.00% beat Natural Alternatives International's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Psyence Biomedical	N/A	N/A	N/A
Natural Alternatives International	-10.13%	-12.21%	-5.30%

Psyence Biomedical has higher earnings, but lower revenue than Natural Alternatives International. Natural Alternatives International is trading at a lower price-to-earnings ratio than Psyence Biomedical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Psyence Biomedical	N/A	N/A	$1.01M	$25.34	0.15
Natural Alternatives International	$129.86M	0.12	-$13.57M	-$2.39	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Psyence Biomedical	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Natural Alternatives International	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Natural Alternatives International had 1 more articles in the media than Psyence Biomedical. MarketBeat recorded 1 mentions for Natural Alternatives International and 0 mentions for Psyence Biomedical. Psyence Biomedical's average media sentiment score of 1.87 beat Natural Alternatives International's score of 0.47 indicating that Psyence Biomedical is being referred to more favorably in the media.

Company	Overall Sentiment
Psyence Biomedical	Very Positive
Natural Alternatives International	Neutral

Psyence Biomedical has a beta of 1.64, suggesting that its share price is 64% more volatile than the broader market. Comparatively, Natural Alternatives International has a beta of 0.38, suggesting that its share price is 62% less volatile than the broader market.

77.4% of Psyence Biomedical shares are owned by institutional investors. Comparatively, 32.4% of Natural Alternatives International shares are owned by institutional investors. 3.6% of Psyence Biomedical shares are owned by company insiders. Comparatively, 20.8% of Natural Alternatives International shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Psyence Biomedical beats Natural Alternatives International on 9 of the 12 factors compared between the two stocks.

Get Psyence Biomedical News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PBM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PBM vs. The Competition

Export

Metric	Psyence Biomedical	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$4.04M	$3.28B	$6.30B	$12.44B
Dividend Yield	N/A	2.36%	2.69%	5.33%
P/E Ratio	0.15	10.28	20.31	22.64
Price / Sales	N/A	317.72	518.49	115.68
Price / Cash	0.35	111.03	41.39	55.53
Price / Book	0.05	6.77	9.98	6.72
Net Income	$1.01M	$24.09M	$3.56B	$337.03M
7 Day Performance	-15.56%	-2.56%	-0.89%	0.09%
1 Month Performance	N/A	N/A	N/A	-1.78%
1 Year Performance	-89.23%	48.90%	28.76%	33.98%

Psyence Biomedical Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PBM Psyence Biomedical	1.1195 of 5 stars	$3.69 -6.6%	N/A	-87.0%	$4.04M	N/A	0.15	N/A	Positive News Short Interest Increase
INAB IN8bio	3.8737 of 5 stars	$1.80 flat	$4.00 +122.2%	-58.5%	$17.73M	N/A	N/A	20	News Coverage Analyst Forecast
KTTA Pasithea Therapeutics	2.841 of 5 stars	$0.70 +0.3%	$3.00 +331.5%	-30.6%	$17.34M	N/A	N/A	3	Positive News Analyst Upgrade High Trading Volume
ANEB Anebulo Pharmaceuticals	N/A	$0.42 -9.6%	N/A	-65.3%	$16.96M	N/A	N/A	4	Gap Up
GRDX Entero Therapeutics	1.3529 of 5 stars	$4.95 +4.4%	N/A	N/A	$16.63M	$40K	N/A	9	Positive News High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PBM) was last updated on 6/4/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Psyence Biomedical (PBM) Competitors

PBM vs. INAB, KTTA, ANEB, GRDX, and NAII

How does Psyence Biomedical compare to IN8bio?

Summary

How does Psyence Biomedical compare to Pasithea Therapeutics?

Summary

How does Psyence Biomedical compare to Anebulo Pharmaceuticals?

Summary

How does Psyence Biomedical compare to Entero Therapeutics?

Summary

How does Psyence Biomedical compare to Natural Alternatives International?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PBM vs. The Competition

Psyence Biomedical Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Psyence Biomedical (PBM) Competitors

PBM vs. INAB, KTTA, ANEB, GRDX, and NAII

How does Psyence Biomedical compare to IN8bio?

Do insiders & institutionals believe in INAB or PBM?

Does the media favor INAB or PBM?

Which has more risk & volatility, INAB or PBM?

Which has higher valuation and earnings, INAB or PBM?

Do analysts recommend INAB or PBM?

Is INAB or PBM more profitable?

Summary

How does Psyence Biomedical compare to Pasithea Therapeutics?

Is PBM or KTTA more profitable?

Which has better valuation & earnings, PBM or KTTA?

Does the media prefer PBM or KTTA?

Do insiders & institutionals have more ownership in PBM or KTTA?

Which has more risk and volatility, PBM or KTTA?

Do analysts prefer PBM or KTTA?

Summary

How does Psyence Biomedical compare to Anebulo Pharmaceuticals?

Do insiders and institutionals hold more shares of PBM or ANEB?

Which has better earnings & valuation, PBM or ANEB?

Do analysts prefer PBM or ANEB?

Is PBM or ANEB more profitable?

Does the media refer more to PBM or ANEB?

Which has more volatility & risk, PBM or ANEB?

Summary

How does Psyence Biomedical compare to Entero Therapeutics?

Does the media refer more to PBM or GRDX?

Do insiders & institutionals hold more shares of PBM or GRDX?

Which has higher earnings and valuation, PBM or GRDX?

Which has more risk and volatility, PBM or GRDX?

Do analysts prefer PBM or GRDX?

Is PBM or GRDX more profitable?

Summary

How does Psyence Biomedical compare to Natural Alternatives International?

Is PBM or NAII more profitable?

Which has higher earnings & valuation, PBM or NAII?

Do analysts recommend PBM or NAII?

Does the media refer more to PBM or NAII?

Which has more risk and volatility, PBM or NAII?

Do insiders and institutionals hold more shares of PBM or NAII?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PBM vs. The Competition

Psyence Biomedical Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools